HOME › DRUGS › RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE (NUCLEOSIDE MODIFIED)
ACTIVE SUBSTANCE / INN

RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE (NUCLEOSIDE MODIFIED)

Brand name(s): mResvia
EMA LISTED
AUTHORISED
Respiratory Syncytial Virus Infections
ACTIVE SUBSTANCE
Respiratory Syncytial Virus Mrna Vaccine (Nucleoside Modified)
REGULATORS
EMA
SPONSORS / MAH
Moderna Biotech Spain, S.L.
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
mResviaModerna Biotech Spain, S.L.Authorised22/08/2024Respiratory Syncytial Virus Infections

FULL INTELLIGENCE ON RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE (NUCLEOSIDE MODIFIED)

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →